The Efficacy of a Posterior sub-Tenon’s Capsule Triamcinolone Injection in Patients with Non-infectious Intermediate Uveitis and Posterior Uveitis

Open access

Abstract

To investigate the efficacy of a posterior sub-Tenon’s capsule triamcinolone injection for treating eyes with non-infectious posterior and intermediate uveitis.

A total of 31 eyes from 20 patients with non-infectious posterior uveitis and 18 eyes from 10 patients with non-infectious intermediate uveitis that inadequately responded to treatment with systemic corticosteroids and second-line immunosuppressive agents were enrolled in the study. All patients received a posterior sub-Tenon’s injection of 20 mg/ml triamcinolone. The parameters we examined included the following: best corrected visual acuity, central foveal thickness, fluorescein angiography score and intraocular pressure.

The mean best corrected visual acuity was significantly improved from the control visit, 0.15±0.30 logMAR (Snellen equivalent 0.7), compared to the baseline measurements, 0.60±0.30 logMAR (Snellen equivalent 0.25; P<0.05). The mean central foveal thickness (CFT) and the mean score for fluorescein angiography (FA) were significantly decreased from the baseline (CFT: 320±34 μm; FA mean score: 5.9±1.9) compared to the twelve-week control visit (CFT: 235±30 μm; FA mean score: 1.2±1.1; P<0.001). Five eyes had intraocular pressure spikes that required a topical anti-glaucomatous treatment.

A posterior sub-Tenon’s injection of triamcinolone can significantly improve visual acuity and decrease macular oedema in patients with non-infectious posterior and intermediate uveitis. Complications were minimal, and there were no eyes that required surgical treatment for elevated intraocular pressure. The results suggest that the posterior sub-Tenon’s injection of triamcinolone is an important form of therapy for non-infectious posterior and intermediate uveitis.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Kempen JH Altaweel MM. The multicenter uveitis steroid treatment trial: rationale design and baseline characteristics. Am J Ophthalmol. 2010;149:550–561

  • 2. Caskun E Celemler P Kimyon G Oner V Kisacik B rrbagci I Mesut OA. Intravitreal Dexamethasone Implant for Treatment of Refractory Behçet Posterior Uveitis: One-year Follow-up Results. Ocular Immunology and inflammation 2015: 23(6)

  • 3. Jonas JB Degenring RF Kreissig I Akkoyun I Kamppeter BA. Intraocular Pressure Elevation after Intravit-real Triamcinolone Acetonide Injection. Ophtalmology 2005;112593-8.

  • 4. Palmberg P. Risk factors for glaucoma progression: Where does intraocular pressure fit in? Arch Ophthalmol 2001;119:897-8.

  • 5. Yamamoto Y Komatsu T Koura Y Nishino K Fukushima A Ueno H. Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection. Can J Ophthalmolo. 2008; 43(1):42-7 doi 10.3129/i07-186

  • 6. Gilles MC Simson JM Billson FA Luo W Penfold P Chua W et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophtalmol 2004;122:336-40

  • 7. Benz MS Murray TG Dubovy SR Katz RS Eifrig CW. Endophtalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophtalmol 2003;121:271-3.

  • 8. Nelson ML Tennant MT Sivalingam A Regillo CD Belmont JB Martidis A. Infectious and presumed non-infectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23(5):686-91

  • 9. Negi AK Browning AC Vernon AS Single perioperative triamcinolone injection versus standard postoperative steroid drops after uneventful phacoemulsification surgery: Randomized controlled trial. J. Cataract Refract Surg. 2006; 32 (3): 468-74

  • 10. McGhee CN. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol 1992; 76:681-684

  • 11. Helm CJ Holland GN. The effect of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995;120:55-64.

  • 12. Yannuzzi L.A. A perspective on the treatment of aphakic cystoid macular edema. Surv Ophthalmol. 1984; 28: 540–553

  • 13. Tugal-Tutkun I. Herbort C.P. Khairallah M. and Angiography Scoring for Uveitis Working Group (ASUWOG). Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010; 30: 539–552

  • 14. Chylack LT Jr Wolfe JK Singer DM Leske MC Bullimore MA Bailey IL et al. The Lens Opacitates Classification Sistem III. The Longitudinal Study of Cataract Study Group. Arch Ophtalmol 1993;111:831-6.

  • 15. Lafranco Dafflon M Tran VT Guex/Crosier Y Herbot CP. Posterior sub-Tenon’s steroid injections for the treatment of posterior ocular inflammation: indications efficacy and side effects. Graefes Arch Clin Exp Ophthalmol 1999;237(4):289-95

  • 16. Jovanović S Vukosavljević M Jovanović M Stanojević-Paović A. Oftalmološke manifestacije hronične sarkoidoze. Ser J Exp Clin Res 2008;9(1):27-30.

  • 17. Zlatanović G Jovanović S Živković M Zlatanović M Srecković S Radotić F. The efficacy of novel therapeutic modalities of isolated ocular vasculitis vs ocular vasculitis as a systemic disease. Med Glas Ljek komore Zenicko-Doboj kantona 2012;9(1):66-73

  • 18. Pickrel A Harris A Ngo S Amireskandari A Stewart E Siesky B. Delivery of Intraocular Triamcinolone Acetonide in the Treatment of Macular Edema Pharmaceutics 2012; 4(1) 230-42.

  • 19. Dal Canto AJ Downs-Kelly E Pery JD. Ptosis and Orbital Fat Prolapse after Posterior Sub–Tenon’s Capsule Triamcinolone Injection. Ophthalmology 2006; 112(6) 1092-97

  • 20. Ferrante P Ramsey A Bunce C Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Experiment Ophthalmol. 2004;32(6):563-8

Search
Journal information
Impact Factor


CiteScore 2018: 0.13

SCImago Journal Rank (SJR) 2018: 0.118
Source Normalized Impact per Paper (SNIP) 2018: 0.079

Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 258 161 16
PDF Downloads 147 90 9